NASDAQ:CALT Calliditas Therapeutics AB (publ) 11/11/2024 Earnings Results & Report $40.00 0.00 (0.00%) As of 10/8/2026 Calliditas Therapeutics AB (publ) was expected to report earnings on November 11, 2024, before market opens. Analysts expected earnings of -$0.1530 per share. Confirmed results have not been posted yet. This page will update with the reported figures, conference call transcript, and earnings documents as they become available. Research:Profile Earnings Announcement Details Announcement DateNovember 11, 2024TimeBefore Market Opens Calliditas Therapeutics AB (publ) EPS ResultsActual EPSN/AConsensus EPS -$0.1530Beat/MissN/AOne Year Ago EPS-$0.58EPS Beat Rate4 of last 8 quartersCalliditas Therapeutics AB (publ) Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesCompany Profile Calliditas Therapeutics AB (publ) Earnings HeadlinesCalliditas Therapeutics’ Setanaxib Study: A Potential Game-Changer for Alport SyndromeAugust 14, 2025 | msn.comCalliditas Therapeutics to Present Four Abstracts at American Society of Nephrology (ASN) Kidney Week 2024October 17, 2024 | tmcnet.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 9 at 1:00 AM | Altimetry (Ad)Calliditas Therapeutics (NASDAQ:CALT) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comDelisting of Calliditas Therapeutics AB (publ) from Nasdaq StockholmSeptember 16, 2024 | prnewswire.comNotice of extraordinary meeting of Calliditas Therapeutics AB (publ)September 3, 2024 | prnewswire.comSee More Calliditas Therapeutics AB (publ) Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Calliditas Therapeutics AB (publ)? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Calliditas Therapeutics AB (publ) and other key companies, straight to your email. Email Address About Calliditas Therapeutics AB (publ)Calliditas Therapeutics AB (publ) (NASDAQ:CALT) was a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly conditions affecting the kidneys and liver. The company was headquartered in Stockholm, Sweden, and operated internationally through partnerships and commercial organizations in Europe and the United States. Calliditas’ lead product was Nefecon, a targeted-release formulation of budesonide developed for adults with primary immunoglobulin A nephropathy (IgA nephropathy), a chronic kidney disease. The product was marketed in the United States as Tarpeyo and in the European Union under the name Kinpeygo. Calliditas also pursued additional clinical programs, including therapies aimed at other rare inflammatory and fibrotic diseases. The company was founded in 2004 as Pharmalink and adopted the Calliditas Therapeutics name in 2018. Renée Aguiar-Lucander served as chief executive officer during the company’s commercialization and international expansion. In 2024, Asahi Kasei Corporation completed its acquisition of Calliditas, and Calliditas subsequently ceased to operate as an independent publicly traded company.View Calliditas Therapeutics AB (publ) ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Applied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt LoadJetBlue's LaGuardia Win Could Change Its Financial Future Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
